STAT2 intron retention regulates immune signaling, correlates with PD-L1 immunotherapy response in lung cancer
Background
Immunotherapy with checkpoint inhibitors has transformed lung cancer treatment, yet patient outcomes remain highly variable. A critical gap exists in understanding the molecular factors that determine who responds well to these therapies. Alternative RNA splicing, a process that generates diverse protein isoforms from a single gene, is increasingly recognized for its role in disease. This study investigates how alternative splicing, particularly within immune-related genes and the type I interferon response pathway, might influence tumor immune responses and patient success with anti-PD-L1 immunotherapy.
Study Design
Researchers utilized long-read RNA sequencing to comprehensively map the alternative RNA splicing landscape in human primary lung adenocarcinomas. They identified and characterized full-length messenger RNA (mRNA) isoforms, focusing on those within immune-related genes. Specifically, they functionally characterized retained introns in the STAT2 gene, investigating how these altered protein isoforms impacted immune signaling and interferon responses. Finally, they correlated these STAT2 splicing patterns with patient survival following anti-programmed death-ligand 1 (PD-L1) immunotherapy.
Results
The study identified more than 149,000 full-length mRNA isoforms in human primary lung adenocarcinomas, with more than half of these being previously unannotated. A significant portion of these novel isoforms occurred in immune-related genes, particularly within the type I interferon response pathway. Functional characterization revealed that retained introns in the STAT2 gene produced altered protein isoforms. These STAT2 isoforms were found to regulate immune signaling and interferon responses, demonstrating a direct functional impact. Importantly, the presence of these STAT2 intron retention patterns:
correlated with patient survival after anti-programmed death-ligand 1 (PD-L1) immunotherapy, positioning alternative splicing as a key regulator of tumor immune responses.
Key Findings
- Long-read RNA sequencing identified >149,000 full-length mRNA isoforms in human lung adenocarcinomas.
Half of the identified mRNA isoforms were previously unannotated.
- Retained introns in the
STAT2gene produced altered protein isoforms. STAT2altered protein isoforms regulated immune signaling and interferon responses.STAT2intron retention correlated with patient survival after anti-PD-L1immunotherapy.
Why It Matters
This research reveals STAT2 intron retention as a novel interferon regulatory axis that significantly correlates with PD-L1 checkpoint inhibitor response in lung cancer. This finding could lead to new biomarkers for predicting immunotherapy efficacy, helping clinicians identify patients most likely to benefit from anti-PD-L1 therapies. For biohackers and researchers, it highlights alternative splicing as a critical, previously underappreciated, mechanism influencing immune responses in cancer. Future work might explore targeting these splicing events to enhance immunotherapy, though a usable protocol is still far off, requiring extensive validation and therapeutic development. It suggests that understanding individual splicing landscapes could personalize cancer treatment strategies.
lung cancer
immunotherapy
pd-l1
stat2
alternative splicing
rna sequencing
